Editorial: The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo vadis

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 4, 2010, Pages 553-556

  Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADVERSE OUTCOME; ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MORTALITY; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME; BLOOD; CHRONIC DISEASE; DRUG LABELING; EVIDENCE BASED MEDICINE; KIDNEY DISEASE; METABOLISM; PRACTICE GUIDELINE; RISK FACTOR; SAFETY; UNITED STATES; UPREGULATION;

ANEMIA; CHRONIC DISEASE; CONSUMER PRODUCT SAFETY; DRUG LABELING; EVIDENCE-BASED MEDICINE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UP-REGULATION;

EID: 77950961681     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00490110     Document Type: Editorial

References (27)

1. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med Oct 30. 361: 2019-2032, 2009
2. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents: Time for a reevaluation. N Engl J Med 362: 189-192, 2010
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolf son M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 20852098, 2006
4. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
5. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998 (Pubitemid 28385655)
6. Singh AK: Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 21: 2-6, 2010
7. Medical officer clinical review: Darbepoetin alfa (Aranesp) for the treatment of anemia associated with chronic renal failure, Rockville, MD, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, 2001. Available at: http://www.fda.gov/ downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDeveloped andApproved/ApprovalApplications/Therapeutic BiologicApplications/ucm086019.pdf. Accessed January 17, 2009
8. FDA Briefing Document May 4, 2004, Oncologic Drugs Advisory Committee. Available at: http://www.fda.gov/ ohrms/dockets/ac/04/briefing/4037b2.htm. Accessed January 17, 2010
9. Aranesp® (darbepoetin alfa) for injection. Available at: http://www.aranesp.com/pdf/aranesp-pi.pdf. Accessed January 17, 2010
10. Procrit label/Epogen label. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2007/103234s5122lbl.pdf. Accessed January 17, 2009
11. FDA Advisory Committee Briefing Document Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee: Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Chronic Renal Failure, Rockville, MD, Food and Drug Administration, 2007. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf. Accessed January 17, 2010
12. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001 (Pubitemid 33021125)
13. Collins AJ, Ma JZ, Ebben J: Impact of hematocrit on morbidity and mortality. Semin Nephrol 20: 345-349, 2000
14. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:1181-1191, 2006
15. Elliott HL: Post hoc analysis: Use and dangers in perspective. JHypertens 14[Suppl 2]: S21-S25, 1996
16. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK: A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 77: 239-246, 2010
17. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004 (Pubitemid 39445919)
18. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
19. Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG: Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis 54: 498-510, 2009
20. Singh AK: Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia - Pro. J Am Soc Nephrol 20: 1436-1441, 2009
21. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: 1337-1343, 2005 (Pubitemid 43246455)
22. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64: 1514-1521, 2003 (Pubitemid 37153820)
23. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18: 3164-3170, 2007 (Pubitemid 350223976)
24. Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L: Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 4: 552-559, 2009
25. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 3: 133-138, 2008
26. Boudville NC, Djurdjev O, Macdougall IC, de Francisco AL, Deray G, Besarab A, Stevens PE, Walker RG, Urena P, Inigo P, Minutolo R, Haviv YS, Yeates K, Agiier ML, MacRae JM, Levin A: Hemoglobin variability in nondialysis chronic kidney disease: Examining the association with mortality. Clin J Am Soc Nephrol 4: 1176-1182, 2009
27. Brunelli SM, Lynch KE, Ankers ED, Joffe MM, Yang W, Thadhani RI, Feldman HI: Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol 3: 1733-1740, 2008